z-logo
Premium
Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach–Merritt phenomenon using four‐drug regimen
Author(s) -
Hauer Julia,
Graubner Ulrike,
Konstantopoulos Nikos,
Schmidt Susanne,
Pfluger Thomas,
Schmid Irene
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20750
Subject(s) - medicine , vincristine , consumptive coagulopathy , kasabach–merritt syndrome , hemangioendothelioma , cyclophosphamide , sarcoma , regimen , prednisolone , methotrexate , coagulopathy , surgery , chemotherapy , pathology
We report a case of a 6‐month‐old girl suffering from a kaposiform hemangioendothelioma of the chest wall, associated with Kasabach–Merritt phenomenon. Despite rapid intervention with cortisone and interferon alpha the tumor led to a life‐threatening clinical condition with progressive growth and consumption coagulopathy under therapy. Because therapy for kaposiform hemangioendotheliomas with a single anti‐angiogenic or anti‐proliferative agent has not been reported to be very successful, we administered vincristine, combined with cyclophosphamide, actinomycin D, and methotrexate in a critically ill patient. After six cycles of the applied four‐drug regiment, the infant was in remission, which has been maintained for 5 months since stopping therapy. Pediatr Blood Cancer 2007;49:852–854. © 2006 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom